Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Taipei City Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT03190005
- Locations
- 🇨🇳
Taipei city hospital, Taipei, Taiwan
CES1 Carriers in the PAPI Study
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 6
- Registration Number
- NCT03188705
- Locations
- 🇺🇸
Amish Research Clinic, Lancaster, Pennsylvania, United States
CES1 Crossover Trial of Clopidogrel and Ticagrelor
- Conditions
- Interventions
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 111
- Registration Number
- NCT03161678
- Locations
- 🇺🇸
Amish Research Clinic, Lancaster, Pennsylvania, United States
Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2018-05-25
- Lead Sponsor
- North Texas Veterans Healthcare System
- Target Recruit Count
- 220
- Registration Number
- NCT03150667
- Locations
- 🇺🇸
Durham VA Medical Center, Durham, North Carolina, United States
🇺🇸VA North Texas Health Care System, Dallas, Texas, United States
P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03119012
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving DAPT Undergoing Dental Procedure.
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Chiang Mai University
- Target Recruit Count
- 428
- Registration Number
- NCT03103685
Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2017-03-13
- Target Recruit Count
- 90
- Registration Number
- NCT03078257
- Locations
- 🇨🇳
First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2018-05-07
- Target Recruit Count
- 80
- Registration Number
- NCT03062462
- Locations
- 🇺🇸
whole blood lumi-aggregometer type 560 VS, Havertown, Pennsylvania, United States
Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor
- Conditions
- Interventions
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 90
- Registration Number
- NCT03039205
- Locations
- 🇧🇷
Instituto do Coração (InCor) - Hospital das Clínicas da FMUSP, Sao Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.